A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Who Discontinued Treatment With Luspatercept or Epoetin Alfa and the COMMANDS Trial.

This article provides information about a clinical trial, NCT06581055, conducted by Bristol-Myers Squibb, which aims to collect real-world data on treatment patterns and clinical outcomes for patients with Myelodysplastic Syndromes (MDS) who discontinued treatment with Luspatercept or Epoetin Alfa and discontinued the COMMANDS trial (NCT03682536). The trial will utilize existing data from patient medical records. The study is observational in nature and focuses on understanding the treatment patterns and clinical outcomes of patients with MDS who have discontinued specific treatments. The study is not yet recruiting participants and is expected to be completed by March 30, 2025. [Extracted from the article]